U.S. Markets closed

Del Mar Pharmaceuticals to accelerate glioblastoma clinical trial in the U.S.

DelMar Pharmaceuticals has received a notice of allowance from the FDA that will enable the company to accelerate the dose-escalation of its ongoing Phase I/II of VAL-083 in refractory glioblastoma multiforme patients. The revised plan will enable the trial to reach higher doses and complete the dose-escalation portion of the clinical trial more quickly by skipping two interim doses: